Pre-Conference Add-on Session*

3:15pm-5:15pm Eastern | 2 Contact Hours

Documentation & Legal Considerations

Tony Thrasher, DO, MBA, CPE, DFAPA

Part 1: Engagement and Empathy in the Era of the Open Note: Keys to High Acuity Documentation
Part 2: EMTALA, HIPAA, and Tarasoff Oh My!: Safely Traversing the Yellow Brick Road of Healthcare Laws

*Pre-Conference Add-on is an additional fee and not included in regular registration. Access the pre-conference session through the add-on option or the One Day Thursday registration option.

Regular Conference Program

5:30pm-7:30pm Eastern | 2 Contact Hours

Keynote: Deep Dive into Medications for Schizophrenia, including Clozapine

Jonathan M. Meyer, MD, DLFAPA

Examine trends and emerging treatments to provide effective care to this population including management of side effects.

6:00am – 7:30am Eastern | No Contact Hours Provided

Product Theater Breakfast

A Comprehensive Review of AUVELITY: A Rapid-Acting Antidepressant That Modulates Both Glutamatergic and Monoaminergic Pathways
Laura K. Melaro, NP; Michele Novella, PMHNP-BC , PMHCNS-BC, APRN
This branded event will highlight the current unmet needs in MDD and present a treatment option with rapid symptom improvement for adult patients with MDD.
Sponsored by Axsome Therapeutics

8:00am – 9:30am Eastern | 1.5 Contact Hours

GLP-1 Medications: Unlocking Potential, Navigating Benefits and Understanding Risks 

Julie B. Perry, DNP

Take an in-depth look at the GLP-1 class of medications exploring the comprehensive pharmacology including mechanism of action, pharmacokinetics, pharmacodynamics, therapeutic uses, dosage, adverse effects/contraindications, and patient considerations. Review current research on potential therapeutic benefits beyond management of diabetes and weight.

9:45am – 11:15am Eastern | 1.5 Contact Hours

Psychedelic Psychopharmacology

Craig Heacock, MD

Discover how Ketamine, psilocybin, and MDMA work in the brain and the psyche, their potential benefits and contraindications, and their interactions with the various classes of psychiatric medications.

11:15am – 1:00pm Eastern | No Contact Hours Provided

Product Theater Lunch

Empowering Treatment Choice With SPRAVATO®
Steven Krozer, PMHNP-BC; Brianne Lienkamp, RN, ANP-BC, PMHNP-BC
Sponsored by Johnson & Johnson Innovative Medicine

1:15pm – 2:15pm Eastern | 1.0 Contact Hours

Keynote: Substance Use and the Brain

Wilson Compton, MD, MPE

Explore brain development from childhood to adulthood, with emphasis on the neuroscience of addiction and substance use. Learn about the “recovering brain” and restoration of dopamine pathways when harmful substances are reduced.

2:30pm – 4:00pm Eastern | 1.5 Contact Hours

Xanax is the Only Thing that Works and Other Tales of Woe: Managing Benzodiazepines in Clinical Practice

Lydia Anne M Bartholow, DNP, PMHNP, CARN-AP

Review best practices for discussing benzodiazepines with patients from a trauma informed perspective and broaden your mindset about prescribing them in the shadow of the opioid crisis.

4:15pm – 5:45pm Eastern | 1.5 Contact Hours

Management of Agitation/Aggression/Dysregulation in the Child & Adolescent Population

Joel Stoddard, MD, MAS

6:15pm – 7:45pm Eastern | No Contact Hours Provided

Product Theater Dinner

Realizing the Potential of Digital Therapeutics: An Evaluation of Clinical Evidence and Prospective Benefits
Lisa Marsch, PhD; Gia Santoro, DNP, APRN, PMHNP-BC
Discover the transformative potential of digital therapeutics (DTx) and take a deep dive into the evidence supporting these technologies as effective treatments for patients with serious mental illnesses. Discuss the rigorous evaluation of DTx and prescription digital therapeutics (PDTs), real-world studies supporting their use, and opportunities for their clinical implementation.
Sponsored by Boehringer-Ingelheim Pharmaceuticals, Inc.

8:00am – 10:00am Eastern | 2 Contact Hours

Deconstructing the Pharmaceutical Industry: Brand vs Generics & What It Means for Practice 

Laura G. Leahy, DrNP, APRN, PMH-CNS/FNP, CARN-AP, FAANP, FAAN

Take a deep dive into the pharmaceutical industry including how drugs get to market, how they move from brand to generic, and why it matters for prescribing practitioners.

10:15am – 11:45am Eastern | 1.5 Contact Hours

Bringing Therapy into Medication Management

Craig Heacock, MD

With a rapid med check model of practice becoming more common, learn how to restore psychotherapy into a therapeutic relationship to help increase medication efficacy.

12:00pm – 1:30pm Eastern | No Contact Hours Provided

Product Theater Lunch 

Learn About a Different Treatment Option for Adults with Schizophrenia: Where Does It Fit in Your Practice?
Hara E. Oyedeji PMHNP-BC, MS, MSed
Don’t miss this opportunity to learn about a different treatment option for adults with schizophrenia. Discover its clinical profile as well as practical considerations for prescribing it. The program also highlights unmet needs in the treatment of schizophrenia.

Sponsored by Bristol Meyers Squibb

1:45pm – 3:15pm Eastern | 1.5 Contact Hours

Advanced Psychopharmacology in Youth: What Works When and Why?

Jeffrey R. Strawn, MD, FAACAP

Learn thoughtful approaches to prescribing and deprescribing antidepressants for children and adolescents, including stopping medications that aren’t working, that cause intolerable side effects or are no longer needed after sustained remission.

3:30pm – 5:00pm Eastern | 1.5 Contact Hours

Geropsychiatric Prescribing Across Disorders and Settings

Kristin Hjartardottir, DNP, PMH-NP; Merrie Kaas, PhD, APRN, PMHCNS-BC, FAAN

Get age-related clinical guidelines and prescribing pearls including Lithium, antidepressants, anticholinergics and medical stability plus setting considerations.

5:30pm – 7:00pm Eastern | No Contact Hours Provided

Product Theater Dinner 

Schizophrenia A-Z: From Pathophysiology to Functional Impact and Management
Andrew Cutler, MD; Amber Hoberg, MSN, APRN, PMHNP-BC
Explore how functional impairment arises from the core symptom domains of schizophrenia and impacts patients’ lives in ways that may not be seen in the clinic. Through an interactive and case-based presentation, review current clinical guidance and ways to assess and manage functional impairment in clinical practice.

Sponsored by Boehringer Ingelheim

8:00am – 9:30am Eastern | 1.5 Contact Hours
Microbiome-Gut-Brain Axis: Integrating Microbiome Modulation for Optimal Psychiatric Medication Management A Case Study Approach in ADHD

David C. Agor, DNP, PMHNP-BC, HIVPCP

Uncover methods for improving microbiome dysbiosis with nutrients to support mental health.

9:45am – 11:15am Eastern | 1.5 Contact Hours

Acetylcholine Neurotransmission, Muscarinic Receptors, and Anticholinergic Burden: Implications for Schizophrenia Spectrum Disorders

Jeremy Mills, DNP, PMHNP-BC

With the advent of novel antipsychotic medications modulating acetylcholine, gain crucial understanding of muscarinic activity and learn about anticholinergic side effects.

11:15am – 1:00pm Eastern | 1 Contact Hour* 

Symposium Lunch

Depression in Focus: Addressing Residual Symptoms for Functional Recovery
This symposium will review personalized treatment plans for major depressive disorder by assessing the benefit-risk profiles of pharmacological options, considering individual patient characteristics and clinical presentations, evaluating evidence-based interventions for detecting and managing residual symptoms, and providing strategies to address disparities in care for minority and underserved populations.

Brooke Kempf, MSN, PMHNP-BC & George Papakostas, MD

This activity is jointly provided by Partners for Advancing Clinical Education and CMEology. Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

*Evaluation administered and contact hour certificate awarded by symposium provider.

1:15pm – 2:45pm Eastern | 1.5 Contact Hours

General Psychiatric Management: Principles and Prescribing Guidelines for Treating Borderline Personality Disorder 

Jeffrey Lucero, MSN, RN, PMHNP-BC

Explore GPM, an evidence based model for BPD treatment with a focus on guidelines for psychiatric prescribing.